Hendra virus is a highly lethal zoonotic pathogen primarily transmitted from flying foxes to horses and occasionally humans, ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

A recent study linking human pegivirus to Parkinson’s is leading scientists to examine the connection between other viral ...

Around 10 million people globally live with the life-threatening virus HTLV-1. Yet it remains a poorly understood disease ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline.

KeyBanc's John Vinh reiterated his Overweight rating for the stock and reaffirmed his $240 target price. GM Earnings Are Coming. Tariffs, EV Tax Credits-and What It Means for the Stock ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory bug.

Lockheed Reports Earnings at a Tough Time. Drones and Defense Budgets Are a Worry. For the quarter, Wall Street is looking for earnings per share of about $6.41 from sales of $18.5 billion, according ...

The vaccine candidate complements Sanofi’s position in the respiratory vaccines space where the company is present in flu and RSV prevention. It allows Sanofi to offer increased physician and patient ...

From daycare outbreaks to the dreaded mouth sores, here's what parents need to know about hand, foot, and mouth disease.

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.